Search results
Added:
1 year ago
HFSA 22 - Dr James Januzzi (Massachusetts General Hospital, US) outlines the findings of the PROVE-HF study, a trial which aimed to determine the effect of sacubitril/valsartan therapy on cardiac biomarkers in patients with mitral regurgitation in heart failure with reduced ejection fraction.
Questions:
1. What was the ideology behind PROVE-HF?
2. What is the mechanism of action behind…
View more
Added:
2 years ago
Dr Douglas Mann (Washington University School of Medicine, Missouri, US) meets host Dr Harriette Van Spall (McMaster University, Hamilton, CA) to discuss the findings from the Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection FractionTrial.
The LIFE trial aimed to address a knowledge gap regarding the efficacy, safety, and tolerability of sacubitril/valsartan in advanced HFrEF…
View more
Added:
11 months ago
ESC-HFA 2023 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sits down with PI, Dr Robert J Mentz (Duke University of Medicine, US) to discuss the findings of the PARAGLIDE-HF trial (NCT03988634).
The PARAGLIDE-HF aimed to evaluate the effects of sacubitril/valsartan compared to valsartan on changes in NT-proBNP, safety and tolerability in HFpEF patients who have…
View more
Added:
3 years ago
Despite advances in diagnostic and treatment modalities, hypertension remains a prevalent medical condition, affecting over 26 % of the adult population, a number expected to rise to nearly 30 % by the year 2025.1 It is a major risk factor for cardiovascular disease morbidity and mortality, including stroke, heart failure, and renal disease.2,3 Numerous investigations have demonstrated the…
View more
Added:
1 year ago
AHA 2022 — Dr Julian Gillmore (University College London, London, UK) joins us to share the key findings from the CRISPR trial (NCT04601051).
This phase 1 study was conducted to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of NTLA-2001 in participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM) or wild type cardiomyopathy (ATTRwt…
View more
Added:
11 months ago
ESC-HFA 2023 – Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss late-breaking science highlights of this year's ESC Heart Failure.
Trials covered in details include:
1:13: First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy
1:42: TRACER-HF:Trientine-HCL for treatment of…
View more
Added:
2 years ago
In this short summary interview, Dr Steven E Nissen (Cleveland Clinic, Cleveland, US) talks about detailed results from the APOLLO study (NCT01960348).
This placebo-controlled double-blind dose-ranging trial investigated the safety and tolerability of SLN360 (Silence Therapeutics plc) in patients with elevated lipoprotein(a).
Discussion Points:
Trial Rationale
Mechanism of Action
Study…
View more
Antoni Martínez-Rubio
Research Area(s) / Expertise:
Author
Added:
3 years ago
Hypertension remains a prevalent, major risk factor for cardiovascular disease (CVD), affecting over one-third of adults in the uS—nearly 74 million people.1 In the uS, elevated blood pressure (BP) contributes to 69% of first myocardial infarctions (MIs), 74% of cases of congestive heart failure (CHF), and 77% of first strokes.1 The total direct and indirect cost of CVD and stroke in the US for…
View more
Added:
1 year ago
ACC.23/WCC—We are joined by Dr Christie Ballantyne (Baylor College of Medicine, US) to discuss the results of a phase 2b clinical trial on the efficacy and safety of MK-0616, an oral macrocyclic PCSK9 inhibitor.In this trial sponsored by Merck Sharp & Dohme LLC, MK-0616 was compared to a placebo in over 380 participants with hypercholesterolemia, whose low-density lipoprotein cholesterol (LDL-C)…
View more
